Invex Therapeutics Ltd. (AU:IXC) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Invex Therapeutics Ltd has announced the retirement of Dr. Megan Baldwin as a Non-executive director, effective 30 June 2024. Baldwin, who joined the biopharmaceutical company in February 2021, played a pivotal role in advancing their leading drug, Exenatide, from Phase II to Phase III clinical trials for treating neurological conditions related to increased intracranial pressure. The company expressed gratitude for her significant contributions and wished her well in future endeavors.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue